McKesson Continues 'Impressive' Execution, RBC Says

12:24 PM EST, 11/05/2026 (MT Newswires) -- McKesson (MCK) continues its "impressive" execution with a broad-based beat-and-raise across all segments in its quarterly results, RBC Capital Markets said in a note Wednesday. Late Wednesday, the firm reported fiscal Q2 adjusted EPS of $11.68 on revenue of $110.96 billion. Analysts polled by FactSet expected $10.72 and $109.90 billion respectively. The results were ahead of consensus estimates and far surpassed its long-range plan targets, driven by specialty prescription volume growth, the report said. The note said the focus is now turning to new initiatives to sustain this growth including strategic acquisitions aimed at broadening its specialty pharma capabilities. Recent acquisitions bring clear strategic adjacencies but synergizing and executing is the name of the game, it added. "We seek more clarity," the report said. RBC kept its sector-perform rating and raised its price target to $965 from $845. Price: 1094.83, Change: +25.39, Percent Change: +2.37